Log in
CVE:MJN

(MJN.V) Stock Forecast, Price & News

C$12.15
-0.23 (-1.86 %)
(As of 03/2/2018)
Add
Today's Range
C$11.90
Now: C$12.15
C$12.47
50-Day Range
C$12.15
MA: C$12.15
C$12.15
52-Week Range
C$1.58
Now: C$12.15
C$14.83
Volume1.39 million shs
Average Volume2.07 million shs
Market CapitalizationC$1.73 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cronos Group Inc, formerly PharmaCan Capital Corp, is a Canada-based cannabis company. The Company operates two Licensed Producers (LPs) regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the ACMPR) and holds a portfolio of investments in other Licensed Producers and ACMPR applicants. Its LPs, Peace Naturals Project Inc. and In The Zone Produce Ltd., are collectively located on over 125 acres of agricultural land. It also holds equity positions in Licensed Producers Whistler Medical Marijuana, Hydropothecary and Abcann Medicinals. Whistler Medical Marijuana is licensed to produce and sell medical marijuana, as well as cultivate cannabis oil. Hydropothecary is licensed to produce medical marijuana. Abcann Medicinals also has license to produce medical marijuana. With interest in five Licensed Producers and two LP applicants, it is focused on building brand portfolio providing patients with personalized care.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryCannabis
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-416-5040004
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market CapC$1.73 billion
Next Earnings DateN/A
OptionableOptionable
C$12.15
-0.23 (-1.86 %)
(As of 03/2/2018)
30 days | 90 days | 365 days | Advanced Chart

Receive MJN News and Ratings via Email

Sign-up to receive the latest news and ratings for MJN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











(MJN.V) (CVE:MJN) Frequently Asked Questions

What stocks does MarketBeat like better than (MJN.V)?

Wall Street analysts have given (MJN.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (MJN.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of (MJN.V)'s key competitors?

What other stocks do shareholders of (MJN.V) own?

Who are (MJN.V)'s key executives?

(MJN.V)'s management team includes the following people:
  • Michael Ryan Gorenstein, President, Chief Executive Officer, Vice Chairman of the Board, Corporate Secretary
  • William Lawrence Hilson, Chief Financial Officer
  • Jason Adler, Director
  • Ryan Roebuck, Director
  • James Rudyk, Director
  • Alan Mark Friedman, Independent Director (Age 45)
  • Michael Howard Krestell, Independent Director

What is (MJN.V)'s stock symbol?

(MJN.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MJN."

How do I buy shares of (MJN.V)?

Shares of MJN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is (MJN.V)'s stock price today?

One share of MJN stock can currently be purchased for approximately C$12.15.

How big of a company is (MJN.V)?

(MJN.V) has a market capitalization of C$1.73 billion.

What is (MJN.V)'s official website?

The official website for (MJN.V) is thecronosgroup.com.

How can I contact (MJN.V)?

(MJN.V)'s mailing address is 720 King St W Suite 320, TORONTO, ON M5V 2T3, Canada. The company can be reached via phone at +1-416-5040004.

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.